Psychotropic medication: Curing illness or creating problems?

Heart

Volumn 95, Issue 23, 2009, Pages 1893-1894

  Jolly, Kate ^a   Langman, Michael J S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPNOTIC SEDATIVE AGENT; POTASSIUM CHANNEL HERG; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANGIOCARDIOGRAPHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CLINICAL TRIAL; COGNITIVE THERAPY; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; SMOKING HABIT; SUDDEN DEATH;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HEART DISEASES; HUMANS; PSYCHOTROPIC DRUGS;

EID: 72049121163     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.179127     Document Type: Editorial

References (16)

1. Kessler RC, Bergland P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
2. Carney RM, Rich MW, TeVelde A, et al. Major depressive disorder in coronary artery disease. Am J Cardiol 1987;60:1273-5.
3. Frasure-Smith N, Lesperence F, Talajic M. Depression following myocardial infarction. Impact on 6 month survival. JAMA 1993;270:1819-29.
4. ENRICHD Investigators. Effects of treating depression and low perceived social support after myocardial infarction. The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA 2003;289:3106-16.
5. Kranz DS, Whittaker KS, Francis JL, et al. Psychotropic medication usage and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndome Evaluation (WISE) study. Heart 2009;95:1901-6.
6. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 paricipants in 54 observational studies. Eur Heart J 2006;27:2763-74.
7. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. J Am Coll Cardiol 2009;53:950-8.
8. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41.
9. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 2006;98:42-7.
10. Sherwood A, Blumenthal JA, Trivedi R, et al, et al. Relationship of depression to death or hospitalisation in patients with heart failure. Arch Intern Med 2007;167:376-3.
11. Jolly K, Gammage MD, Cheng KK, et al. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol (in press).
12. Milnes JT, Crociani O, Arcangeli A, et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003;139:887-98.
13. Hancox JC, Mitcheson JS. Combined HERG channel inhibition and disruption of trafficking in induced long QT syndrome by fluoxetine: a case study in cardiac safety pharmacology. Br J Pharmacol 2006;149:457-9.
14. Witchel HJ, Pabbathi VK, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS lett 2002;512:59-66.
15. Druss BJ, Rosenheck RA, Desai MM, et al. Quality of preventive medical care for patients with mental disorders. Med Care 2002;40:129-36.
16. Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160:1818-23.